October 2012

Dear Colleagues,

Welcome to the workshop on Delivering Affordable Cancer Care in the 21st Century, hosted by the Institute of Medicine’s National Cancer Policy Forum.

Rising health care costs, including the costs of cancer care, represent a central challenge in the United States. Advances in early detection, prevention, and treatment of cancer have resulted in consistently falling cancer death rates, but the national cost of cancer care is substantial and is expected to increase significantly due to the aging population. The average cost of treating the most common cancers has also increased, and as more expensive targeted therapies and other new technologies become the standard of care, the costs of cancer care are projected to escalate more rapidly in the near future. Despite high expenditures, disparities in cancer outcomes persist.

Workshop presentations and discussions will examine the causes of rising costs in cancer care and suggest potential ways to curb these costs while maintaining or improving the quality of care. Individual speakers and attendees can suggest potential paths forward, and presentations and discussions will inform an ongoing IOM consensus study, Improving the Quality of Cancer Care: Addressing the Challenges of an Aging Population. More information about the consensus study is available in this briefing book and at:
http://www.iom.edu/Activities/Quality/QualityCancerCareAging.aspx

We encourage you to participate actively in workshop discussions. A summary of this workshop will be published by the National Academies Press, and may incorporate your comments and ideas. In addition, the workshop will be webcast and a video archive will be available at http://www.iom.edu/Activities/Disease/NCPF/2012-OCT-08.aspx.

Sincerely,

Patricia A. Ganz, M.D.  Ya-Chen Tina Shih, Ph.D.
Co-Chair, Workshop Planning Committee  Co-Chair, Workshop Planning Committee
University of California, Los Angeles  The University of Chicago
National Cancer Policy Forum Workshop on Delivering Affordable Cancer Care in the 21st Century

AGENDA

The Keck Center of the National Academies
500 Fifth Street, NW - Room 100
Washington, DC 20001

Workshop Aims

In 2009, the National Cancer Policy Forum convened Assessing and Improving Value in Cancer Care: A Workshop (http://www.nap.edu/catalog.php?record_id=12644) that examined the implications of value considerations in cancer care. This workshop, Delivering Affordable Cancer Care in the 21st Century, is intended to build upon the 2009 workshop discussions and further examine the challenges of delivering affordable cancer care throughout the continuum of screening, diagnosis, treatment, and surveillance. Workshop presentations and discussions will highlight the causes of the rising costs of cancer care and suggest potential ways to curb these costs, with the goal of ensuring that patients have access to high quality, affordable cancer care.

The goals of the workshop include:

- Summarize current evidence on the overuse, underuse, and misuse of medical technology throughout the continuum of cancer care;
- Identify problems in the system that could be modified, and suggest changes to address them; and
- Discuss policy issues related to the value, cost containment, and reimbursement of cancer care as well as the economic incentives of innovation and technology diffusion in cancer.

October 8, 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45 am</td>
<td>Breakfast and Registration</td>
</tr>
</tbody>
</table>
| 8:15 am | Welcome from the National Cancer Policy Forum  
John Mendelsohn, MD Anderson Cancer Center; Chair, National Cancer Policy Forum |
| 8:20 am | Opening Remarks  
Harvey V. Fineberg, President of the Institute of Medicine |
| 8:35 am | Workshop Introduction and Overview  
Patricia A. Ganz, University of California, Los Angeles, Workshop Co-Chair  
Tina Shih, University of Chicago, Workshop Co-Chair |
| 8:40 am | Session 1: Overview  
Current Challenges to the Delivery of Affordable Cancer Care  
Moderator: Patricia A. Ganz, University of California, Los Angeles |
| 8:45 am | How Should We Define Value in Cancer Care: Summary of the 2009 NCPF Workshop, Assessing and Improving Value in Cancer Care  
- Scott Ramsey, Fred Hutchinson Cancer Research Center |
| 9:00 am | What is the Economic Burden for Patients and Their Families?  
- Veena Shankaran, Fred Hutchinson Cancer Research Center |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:15 am</td>
<td>Delivering Affordable Cancer Care in High Income Countries: What are the Known Challenges?</td>
<td>• Jeffrey Peppercorn, Duke University</td>
</tr>
<tr>
<td>9:30 am</td>
<td>Projections on the Economic Burden of Cancer in the United States</td>
<td>• Robin Yabroff, National Cancer Institute</td>
</tr>
<tr>
<td>9:45 am</td>
<td>Where Are the Health Care Cost Savings?</td>
<td>• Ezekiel Emanuel, University of Pennsylvania</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>11:00 am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11:15 am</td>
<td>Keynote Presentation</td>
<td>• Mark McClellan, Brookings Institution</td>
</tr>
<tr>
<td>12:00 pm</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Session 2: Cancer Screening and Diagnosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Tina Shih, University of Chicago</td>
<td></td>
</tr>
<tr>
<td>1:05 pm</td>
<td>Culture of Cancer Screening and Diagnosis: Disparities in Spite of High Costs</td>
<td>• Otis Brawley, American Cancer Society</td>
</tr>
<tr>
<td>1:25 pm</td>
<td>Over- and Underuse of Colorectal Cancer Screening</td>
<td>• James Goodwin, University of Texas Medical Branch</td>
</tr>
<tr>
<td>1:40 pm</td>
<td>CT Scans for Lung Cancer Screening</td>
<td>• Denise Aberle, University of California, Los Angeles</td>
</tr>
<tr>
<td>1:55 pm</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>2:30 pm</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>2:45 pm</td>
<td>Session 3: Cancer Treatment and Surveillance</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Lowell Schnipper, Beth Israel Deaconess Medical Center</td>
<td></td>
</tr>
<tr>
<td>2:50 pm</td>
<td>ASCO’s Top 5 Initiative, A Way to Improve Quality and Reduce Cost of Care</td>
<td>• Lowell Schnipper, Beth Israel Deaconess Medical Center</td>
</tr>
<tr>
<td>3:05 pm</td>
<td>Biologics and Pharmacologics</td>
<td>• Deborah Schrag, Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>3:20 pm</td>
<td>Role of Compendia in Determining what Drugs are Reimbursed</td>
<td>• Amy Abernethy, Duke University</td>
</tr>
<tr>
<td>3:35 pm</td>
<td>Toward Accountable Care in Radiation Oncology</td>
<td>• Justin Bekelman, University of Pennsylvania</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>3:50 pm</td>
<td>New Technologies in Surgery</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Jim Hu, University of California, Los Angeles</td>
<td></td>
</tr>
<tr>
<td>4:05 pm</td>
<td>Novel Models of Supportive Care in Patients with Advanced Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Jennifer Temel, Massachusetts General Hospital</td>
<td></td>
</tr>
<tr>
<td>4:20 pm</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>5:15 pm</td>
<td>Wrap up Day 1 and Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>October 9, 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am</td>
</tr>
<tr>
<td>8:00 am</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>8:05 am</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>8:20 am</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>8:35 am</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>8:50 am</td>
</tr>
<tr>
<td>9:20 am</td>
</tr>
<tr>
<td>9:30 am</td>
</tr>
<tr>
<td>9:35 am</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>9:50 am</td>
</tr>
<tr>
<td>10:05 am</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>10:20 am</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>10:35 am</td>
</tr>
<tr>
<td>Time</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td>11:20 am</td>
</tr>
<tr>
<td>11:30 am</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>11:40 am</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>12:50 pm</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>1:00 pm</td>
</tr>
</tbody>
</table>
Workshop Notes

- Please identify your name and affiliation prior to asking questions at the microphone.

- We will be filming a live webcast of the meeting. A link to the webcast feed is available at: [http://www.iom.edu/Home/Activities/Disease/NCPF/2012-OCT-08/Webcast.aspx](http://www.iom.edu/Home/Activities/Disease/NCPF/2012-OCT-08/Webcast.aspx)

- Please use hashtag #IOMncpf to tweet about the workshop.

- An archive of the video webcast, speaker and moderator bios, and presentation slides will be available at: [http://www.iom.edu/Activities/Disease/NCPF/2012-OCT-08.aspx](http://www.iom.edu/Activities/Disease/NCPF/2012-OCT-08.aspx)

- Workshop presentations and discussions will inform an ongoing consensus study, Committee on Improving the Quality of Cancer Care: Addressing the Challenges of an Aging Population. More information about the study is available in this briefing book and at: [http://www.iom.edu/Activities/Quality/QualityCancerCareAging.aspx](http://www.iom.edu/Activities/Quality/QualityCancerCareAging.aspx)

- A summary of the workshop will be published following Institute of Medicine procedures. Rapporteurs will compose the summary from the workshop transcript, and external reviewers will examine the summary to make sure it accurately reflects workshop discussions and conforms to institutional policies.

- Interested in receiving IOM and National Cancer Policy Forum Email Updates? Sign up at: [http://www.iom.edu/Global/Media%20Room/Updates.aspx](http://www.iom.edu/Global/Media%20Room/Updates.aspx)

- Like the IOM on Facebook: [www.facebook.com/theIOM](http://www.facebook.com/theIOM)

- Follow the IOM on Twitter: [@theIOM](http://twitter.com/theIOM)

- Follow the IOM on LinkedIn: [www.linkedin.com](http://www.linkedin.com)
The National Cancer Policy Forum

The National Cancer Policy Forum (NCPF) provides a continuous focus on cancer policy at the Institute of Medicine (IOM). IOM forums are designed to allow government, industry, academic, and other representatives to meet, confer, and plan on subject areas of mutual interest. The objectives of the NCPF are to identify emerging high priority policy issues in the nation’s effort to combat cancer and to examine those issues through convening activities that promote discussion about potential opportunities for action. These activities inform stakeholders about critical policy issues through published reports, and often provide input for planning formal IOM consensus committee studies.

The IOM established the NCPF on May 1, 2005, to succeed the National Cancer Policy Board (1997-2005, the Board). The Board brought together leaders from the cancer community to identify and conduct studies and other activities contributing to cancer research, prevention, treatment, and public awareness. The combination of multidisciplinary expertise (basic, clinical, and public health scientists, consumers, and advocates) and resources (grants from the National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC), as well as smaller contributions from private sector organizations) allowed the Board to produce a remarkably original and diverse body of work contributing to improvements in knowledge and public policy.

The NCPF continues to provide a focus within the National Academies for the consideration of issues in science, clinical medicine, public health, and public policy relevant to the goals of preventing, palliating, and curing cancer. The NCPF builds upon the work of the Board and enjoys a closer working relationship with its federal and non-federal sponsors. As a forum rather than a board, sponsors are full members with the academic, consumer, and policy community members. They bring ideas and requests to the deliberations and have the advantage of playing an active part in the discussions. Governmental sponsors represented on the NCPF include the NCI and CDC, and non-governmental sponsors include the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, the Association of American Cancer Institutes, Bristol-Myers Squibb, C-Change, the CEO Roundtable on Cancer, GlaxoSmithKline Oncology, Novartis, the Oncology Nursing Society, and Sanofi Oncology. Additional distinguished experts from the cancer community are also appointed as members to serve three-year terms. The NCPF operates under the aegis of the IOM Board on Health Care Services.

The NCPF enables all members to be full participants in identifying and debating critical policy issues in cancer care and research, and in examining potential opportunities for actions. These convening activities result in published reports that are available to the public and may provide input to planning formal IOM consensus committee studies. Ideas for committee studies that emerge from the NCPF’s deliberations are handed off to an appropriate ad hoc committee appointed by IOM. The studies are conducted by NCPF staff and the committees often include one or more members of the NCPF. Forum sponsors often actively pursue activities to facilitate the implementation of recommendations made in these consensus reports, as well as suggestions put forth in NCPF workshops.

500 Fifth Street, NW, Washington, DC 20001  Ph: 202-334-1233  Fax: 202-334-2862
www.iom.edu/Activities/Disease/NCPF
National Cancer Policy Forum Reports:

Spin-off IOM consensus committee reports:

Membership of the Forum:
Chair - John Mendelsohn, MD, President, MD Anderson Cancer Center
Vice Chair - Patricia Ganz, MD, Professor of Medicine, Jonsson Comprehensive Cancer Center
Amy Abernethy, MD, Director, Duke University School of Medicine Cancer Care Research Program
Rafael Amado, MD, Senior Vice President and Head of GlaxoSmithKline Oncology R&D
Fred Appelbaum, MD, Director, Clinical Research, Fred Hutchinson Cancer Research Center
Peter Bach, MD, MAPP, Member, Memorial Sloan-Kettering Cancer Center
Edward Benz, MD, President, Dana-Farber Cancer Institute
Monica Bertagnolli, MD, Professor of Surgery, Harvard University Medical School
Otis Brawley, MD, Chief Medical Officer and Executive Vice President, American Cancer Society
Michael Caligiuri, MD, Director, Ohio State University Cancer Center, past President, AACI
Renzo Canetta, MD, Vice President, Oncology Global Clinical Research, Bristol-Myers Squibb
Michaele Chamblee Christian, MD, Retired
William Dalton, PhD, MD, CEO, M2Gen, H. Lee Moffitt Cancer Center
Wendy Demark-Wahnefried, PhD, RD, Professor and Chair, University of Alabama, Birmingham
Robert Erwin, MS, President, Marti Nelson Cancer Foundation
Roy Herbst, MD, PhD, Chief of Medical Oncology, Yale Cancer Center
Thomas Kean, MPH, President and CEO, C-Change
Douglas Lowy, MD, Deputy Director, Division of Basic Science, NCI
Daniel R. Masys, MD, Affiliate Professor, Biomedical Informatics, University of Washington
Martin Murphy, PhD, DMEdSc, Chief Executive Officer, CEO Roundtable on Cancer
Brenda Nevidjon, RN, MSN, Professor, Duke University School of Nursing, past President, ONS
Steven Piantadosi, MD, PhD, Director, Samuel Oschin Comprehensive Cancer Institute
Lisa Richardson, MD, MPH, Associate Director, Division of Cancer Prevention and Control, CDC
Debasish Roychowdhury, MD, Senior Vice President, Global Oncology, Sanofi
Ya-Chen Tina Shih, PhD, Director, Program in the Economics of Cancer, University of Chicago
Ellen Sigal, PhD, Chairperson and Founder, Friends of Cancer Research
Steven Stein, MD, Senior Vice President, US Clinical Development & Medical Affairs, Novartis
John Wagner, MD, PhD, Vice President, Clinical Pharmacology, Merck Research Laboratories
Ralph Weichselbaum, MD, Chairman, Radiation and Cellular Oncology, University of Chicago
Janet Woodcock, MD, Director, Center for Drug Evaluation and Research, FDA

Forum Director: Sharyl Nass, PhD
Upcoming NCPF Workshop

Implementing a National Cancer Clinical Trials System for the 21st Century, Workshop #2
A workshop hosted by the American Society for Clinical Oncology and the Institute of Medicine’s National Cancer Policy Forum

February 11-12, 2013
The Keck Center of the National Academies - Room 100
500 Fifth Street, NW, Washington, DC 20001

Statement of Task
An ad hoc committee will plan and conduct two public workshops whose agendas will identify and examine ongoing activities to implement the recommendations put forth in the IOM consensus report, A National Cancer Clinical Trials System for the 21st Century. The first workshop was held in early 2011 and invited all stakeholders charged with making changes to the system (e.g., National Cancer Institute (NCI), Food and Drug Administration (FDA), Office for Human Research Protections (OHRP), Centers for Medicare and Medicaid Services (CMS), NCI Cooperative Group Chairs, drug/biotech/device industry, patient advocates, investigators at academic and community sites, and private payers) to discuss what changes they planned to implement in response to the IOM recommendations. The second workshop to be held in early 2013 will reconvene key stakeholders to discuss progress made to date and to identify additional actions to take. Individually-authored summaries of the workshops will subsequently be prepared by a designated rapporteur.

Agenda
The agenda, which is in development, will include sessions on:
Updates from NCI and NCTN Components: Progress to Date
Funding for Cancer Clinical Trials
Prioritization and Ongoing/Future Challenges
Accelerating Innovation through Effective Partnerships
Regulatory Issues

For more information, or to register for the meeting, see:
http://www.iom.edu/Activities/Disease/NCPF.aspx

Planning Committee Roster

Chair
Monica Marie Bertagnolli, M.D.
Professor of Surgery
Harvard University Medical School
Associate Surgeon
Dana-Farber Cancer Institute
Group Chair, Cancer and Leukemia Group B
Brigham and Women’s Hospital
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Amy P. Abernethy, M.D.</strong></td>
<td>Associate Professor of Medicine</td>
</tr>
<tr>
<td></td>
<td>Division of Medical Oncology</td>
</tr>
<tr>
<td></td>
<td>Department of Medicine</td>
</tr>
<tr>
<td></td>
<td>Duke University School of Medicine</td>
</tr>
<tr>
<td></td>
<td>Director, Duke Cancer Care Research Program</td>
</tr>
<tr>
<td></td>
<td>Duke University Medical Center</td>
</tr>
<tr>
<td><strong>Michael A. Caligiuri, M.D.</strong></td>
<td>Director, Comprehensive Cancer Center</td>
</tr>
<tr>
<td></td>
<td>CEO, James Cancer Hospital &amp; Solove Research Institute</td>
</tr>
<tr>
<td></td>
<td>Foundation Professor of Cancer Research</td>
</tr>
<tr>
<td></td>
<td>The Ohio State University</td>
</tr>
<tr>
<td><strong>Renzo Canetta, M.D.</strong></td>
<td>Vice President</td>
</tr>
<tr>
<td></td>
<td>Oncology Global Clinical Research</td>
</tr>
<tr>
<td></td>
<td>Bristol-Myers Squibb Company</td>
</tr>
<tr>
<td><strong>Michaële Chamblee Christian, M.D.</strong></td>
<td>Retired</td>
</tr>
<tr>
<td></td>
<td>(Former Director, CTEP, NCI)</td>
</tr>
<tr>
<td><strong>James H. Doroshow, M.D.</strong></td>
<td>Deputy Director for Clinical and Translational Research</td>
</tr>
<tr>
<td></td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td><strong>Patrick Gavin</strong></td>
<td>President</td>
</tr>
<tr>
<td></td>
<td>Patrick Gavin R.Ph. Consulting LLC</td>
</tr>
<tr>
<td><strong>Gregory H. Reaman, M.D.</strong></td>
<td>Associate Director</td>
</tr>
<tr>
<td></td>
<td>Office of Hematology and Oncology Products, OND</td>
</tr>
<tr>
<td></td>
<td>Center for Drug Evaluation and Research</td>
</tr>
<tr>
<td></td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td><strong>George W. Sledge, Jr., M.D.</strong></td>
<td>Professor of Medicine and Pathology and Distinguished Professor</td>
</tr>
<tr>
<td></td>
<td>Indiana University Simone Cancer Center</td>
</tr>
<tr>
<td><strong>Ralph R. Weichselbaum, M.D.</strong></td>
<td>Daniel K. Ludwig Professor</td>
</tr>
<tr>
<td></td>
<td>Chairman</td>
</tr>
<tr>
<td></td>
<td>Department of Radiation and Cellular Oncology</td>
</tr>
<tr>
<td></td>
<td>Director</td>
</tr>
<tr>
<td></td>
<td>Ludwig Center for Metastasis Research</td>
</tr>
<tr>
<td></td>
<td>The University of Chicago Medical Center</td>
</tr>
<tr>
<td><strong>Robin Zon, M.D., FACP</strong></td>
<td>MHO Partner/VP</td>
</tr>
<tr>
<td></td>
<td>NICRC-CCOP Principal Investigator</td>
</tr>
</tbody>
</table>
2012 Membership Roster

**John Mendelsohn, MD** – Chair  
Co-Director, Khalifa Institute for Personalized Cancer Therapy  
The University of Texas  
MD Anderson Cancer Center

**Patricia A. Ganz, MD** – Vice Chair  
Professor, Schools of Medicine & Public Health, Division of Cancer Prevention & Control Research  
Jonsson Comprehensive Cancer Center  
University of California, Los Angeles

**Amy P. Abernethy, MD**  
Director, Center for Learning Health Care  
Duke Clinical Research Institute  
Director, Duke Cancer Care Research Program, Duke Cancer Institute  
Associate Professor  
Division of Medical Oncology  
Duke University School of Medicine

**Rafael G. Amado, MD**  
Senior Vice President  
Head of GSK-Oncology R&D  
GlaxoSmithKline Oncology

**Fred Appelbaum, MD**  
Director, Clinical Research Division  
Fred Hutchinson Cancer Research Center

**Peter B. Bach, MD, MAPP**  
Attending Physician  
Health Outcomes Research Group  
Department of Epidemiology and Biostatistics  
Memorial Sloan-Kettering Cancer Center

**Edward J. Benz, Jr., MD**  
Director, Harvard Cancer Center  
Harvard School of Medicine  
President, Dana-Farber Cancer Institute

**Otis W. Brawley, MD**  
Chief Medical Officer  
American Cancer Society

**Monica Marie Bertagnolli, MD**  
Professor of Surgery, Harvard University Medical School; Associate Surgeon  
Dana-Farber Cancer Institute  
Group Chair, Cancer and Leukemia Group B  
Brigham and Women’s Hospital

**Michael A. Caligiuri, MD**  
Director, Comprehensive Cancer Center  
CEO, James Cancer Hospital & Solove Research Institute  
Foundation Professor of Cancer Research  
The Ohio State University

**Rafaela Chamblee Christian, MD**  
retired from NCI

**William S. Dalton, PhD, MD**  
President/CEO & Center Director  
Moffitt Cancer Center & Research Institute  
University of South Florida

**Wendy Demark-Wahnefried, PhD, RD**  
Professor and Webb Endowed Chair of Nutrition Sciences  
Associate Director, Cancer Prevention & Control  
UAB Comprehensive Cancer Center  
University of Alabama at Birmingham

**Robert L. Erwin, MS**  
President  
Marti Nelson Cancer Foundation

**Roy S. Herbst, MD, PhD**  
Chief of Medical Oncology  
Yale Cancer Center

**Thomas J. Kean, MPH**  
President and Chief Executive Officer  
C-Change
Douglas R. Lowy, MD
Deputy Director, Center for Cancer Research
Chief, Basic Research Laboratory
Deputy Director, National Cancer Institute

Daniel R. Masys, MD
Affiliate Professor, Biomedical and Health Informatics
Department of Medical Education and Biomedical Informatics, School of Medicine
University of Washington

Martin J. Murphy, PhD, DMedSc
Chief Executive Officer
CEO Roundtable on Cancer

Brenda Nevidjon, MSN, RN, FAAN
Past-President, Oncology Nursing Society
Clinical Professor; Specialty Director, Nursing & Healthcare Leadership
Duke University School of Nursing

Steven Piantadosi, MD, PhD
Phase One Foundation Endowed Chair & Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center

Lisa C. Richardson, MD, MPH
Associate Director for Science
Division of Cancer Prevention and Control Centers for Disease Control and Prevention

Debasish Roychowdhury, MD
Senior Vice President - Global Oncology
Member of the Global Leadership Team
Sanofi Oncology

Ya-Chen Tina Shih, PhD
Associate Professor, Section of Hospital Medicine, Department of Medicine
Director, Program in the Economics of Cancer University of Chicago

Ellen V. Sigal, PhD
Chairperson and Founder
Friends of Cancer Research

Steven Stein, MD
Senior Vice President
US Clinical Development and Medical Affairs
Novartis Oncology
Novartis Pharmaceuticals Corporation

John A. Wagner, MD, PhD
Vice President, Early Development Project & Pipeline Lead
Head, Global Project Management
Merck & Co., Inc.

Ralph R. Weichselbaum, MD
Daniel K. Ludwig Professor
Chairman, Department of Radiation & Cellular Oncology
Director, Ludwig Center for Metastasis Research
The University of Chicago Medical Center

Janet Woodcock, MD
Director
Center for Drug Evaluation and Research
Food and Drug Administration

FORUM STAFF:

Sharyl Nass, PhD
Director, National Cancer Policy Forum
snass@nas.edu

Laura Levit, JD
Program Officer
llevit@nas.edu

Erin Balogh, MPH
Associate Program Officer
ebalogh@nas.edu

Roger Herdman, MD
Director, Board on Health Care Services
rherdman@nas.edu

Sharon Murphy, MD
Scholar-in-Residence
smurphy@nas.edu

Pam Lighter
Research Assistant
plighter@nas.edu

Michael Park
Senior Program Assistant
mpark@nas.edu
Delivering Affordable Cancer Care in the 21st Century
An Institute of Medicine National Cancer Policy Forum Workshop

Statement of Task
An ad hoc committee will plan and conduct a public workshop, whose agenda will identify and examine key drivers behind the escalating cost of cancer care, as well as potential policy changes that could modify those drivers and help ensure affordable cancer care. The workshop, which will feature invited presentations and discussion, may examine topics such as:

• the use of biomarker and imaging tests,
• the impact of new technologies,
• the role of medical homes and care coordination; and
• the influence of healthcare payment mechanisms.

Workshop participants will also discuss potential ways to reduce cost escalation in cancer care while improving the quality of care and patient outcomes. A single individually authored summary of the workshop will be prepared by a designated rapporteur based on the information gathered and the discussions held.

Planning Committee Roster

<table>
<thead>
<tr>
<th>Co-Chair</th>
<th>Co-Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patti Ganz, MD</td>
<td>Tina Shih, PhD</td>
</tr>
<tr>
<td>Director, Cancer Prevention and Control Research Jonsson Comprehensive Cancer Center University of California, Los Angeles</td>
<td>Associate Professor, Section of Hospital Medicine Director, Program in the Economics of Cancer Department of Medicine The University of Chicago</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Peter Bach, MD, MAPP</th>
<th>Scott Ramsey, MD, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Associate Attending Physician Memorial Sloan-Kettering Cancer Center</td>
<td>Director, Cancer Prevention Program Division of Public Health Science Fred Hutchinson Cancer Research Center</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ezekiel Emmanuel, MD, PhD</th>
<th>Lowell Schnipper, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Head of the Department of Bioethics The Clinical Center of the National Institutes of Health Special Advisor for Health Policy to the Director of OMB</td>
<td>Chief Hematology/Oncology Beth Israel Deaconess Medical Center</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tom Kean, MPH</th>
<th>Deborah Schrag, MD, MPH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Director C-Change - Collaborating to Conquer Cancer</td>
<td>Associate Professor of Medicine Harvard Medical School</td>
</tr>
</tbody>
</table>
Speakers, Moderators, & Discussants

Denise R. Aberle, MD
Professor of Radiology and Bioengineering
Vice Chair, Research
Department of Radiological Sciences
David Geffen School of Medicine
University of California, Los Angeles

Amy P. Abernethy, MD
Director, Center for Learning Health Care
Duke Clinical Research Institute
Director, Duke Cancer Care Research Program, Duke Cancer Institute
Associate Professor
Division of Medical Oncology
Duke University School of Medicine

Peter B. Bach, MD, MAPP
Attending Physician & Director
Center for Health Policy and Outcomes
Department of Epidemiology and Biostatistics
Memorial Sloan-Kettering Cancer Center

Justin E. Bekelman, MD
Assistant Professor of Radiation Oncology
Member, Abramson Cancer Center
Senior Fellow, Leonard Davis Institute for Health Economics
Perelman School of Medicine
University of Pennsylvania

Otis W. Brawley, MD
Chief Medical Officer
American Cancer Society

Renzo Canetta, MD
Vice President
Oncology Global Clinical Research
Bristol-Myers Squibb Company

Susan Dentzer
Editor-in-Chief
Health Affairs

Craig Earle, MD, MSc, FRCPC
Medical Oncologist, Odette Cancer Centre
Professor of Medicine, University of Toronto
Senior Scientist, Institute for Clinical Evaluative Sciences
Director, Health Services Research for Cancer Care, Ontario Institute for Cancer Research

Peter D. Eisenberg, MD, FACP
Medical Director
Marin Specialty Care

Ezekiel J. Emanuel, MD, PhD
Diane v.S. Levy & Robert M. Levy University Professor
Vice Provost for Global Initiatives
Chair, Department of Medical Ethics & Health Policy, Perelman School of Medicine
University of Pennsylvania

Robert L. Erwin, MS
President
Marti Nelson Cancer Foundation

Harvey V. Fineberg, MD, PhD
President
Institute of Medicine

Patricia A. Ganz, MD
Professor, Schools of Medicine & Public Health, Division of Cancer Prevention & Control Research
Jonsson Comprehensive Cancer Center
University of California, Los Angeles

James S. Goodwin, MD
George and Cynthia Mitchell Distinguished Chair in Geriatric Medicine
Director, Sealy Center on Aging
University of Texas Medical Branch

Robert J. Green, MD, MSCE
Medical Oncologist and Chief Medical Officer
Cancer Clinics of Excellence

Jessie Gruman, PhD
President
Center for Advancing Health
Jim C. Hu, MD, MPH
Henry E. Singleton Chair in Urology
Director, Minimally Invasive Urology
Co-Director, Center for Advanced Surgical and Interventional Technology
Director, Urology Procedures Unit
University of California, Los Angeles

Thomas J. Kean, MPH
President and Chief Executive Officer
C-Change

Barnett S. Kramer, MD, MPH
Director
Division of Cancer Prevention
National Cancer Institute

Allen S. Lichter, MD
Chief Executive Officer
American Society of Clinical Oncology

Mark B. McClellan, MD
Senior Fellow
Director, Engelberg Center for Health Care Reform
Leonard D. Schaeffer Chair in Health Policy Studies
The Brookings Institution

Joan Mendelsohn, MD
Co-Director, Khalifa Institute for Personalized Cancer Therapy
The University of Texas
MD Anderson Cancer Center

Therese M. Mulvey, MD
Physician-in-Chief
Southcoast Centers for Cancer Care

Lee N. Newcomer, MD
Senior Vice President, Oncology
UnitedHealthcare

Jeffrey Peppercorn, MD, MPH
Associate Professor of Medicine
Division of Medical Oncology
Faculty Associate, Trent Center for Bioethics
duke University Medical Center

Scott Ramsey, MD, PhD
Full Member, Cancer Prevention Program
Director, Research and Economic Assessment in Cancer and Healthcare (REACH)
Fred Hutchinson Cancer Research Center
Professor, Schools of Medicine, Pharmacy, and Institute for Public Health Genetics
University of Washington

Lowell E. Schnipper, MD
Theodore W. & Evelyn G. Berenson Professor
Department of Medicine
Harvard Medical School
Clinical Director, Cancer Center
Chief, Division of Hematology/Oncology
Beth Israel Deaconess Medical Center

Deborah Schrag, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Deputy Associate Director, Population Sciences
Dana-Farber/Harvard Cancer Center
Attending Physician
Dana-Farber Cancer Institute

Joanne Schottinger, MD
Clinical Lead, Cancer
Kaiser Permanente Care Management Institute
Assistant Medical Director
Southern California Permanente Medical Group

Veena Shankaran, MD
Assistant Professor of Medical Oncology
University of Washington School of Medicine
Assistant Member, Clinical Research Division
Fred Hutchinson Cancer Research Center

Ya-Chen Tina Shih, PhD
Associate Professor, Section of Hospital Medicine
Department of Medicine
Director, Program in the Economics of Cancer
University of Chicago

Jennifer Temel, MD
Associate Professor of Medicine
Harvard Medical School
Clinical Director, Thoracic Oncology
Massachusetts General Hospital

Robin Yabroff, PhD, MBA
Epidemiologist
Health Services and Economics Branch
National Cancer Institute
Registered Attendees

Darrin Ahrens  
Accretive Health

Claude Desjardins  
Johns Hopkins School of Public Health

Carolyn Aldige  
Prevent Cancer Foundation

James Dignam  
University of Chicago

Matthew Banegas  
National Cancer Institute

Kate Dobson  
Cancer Clinics of Excellence

Andrew Baum  
Citi

Marteey Dodoo  
Neiman Health Policy Institute

Giselle Bleecker  
MMS

David Eagle  
Lake Norman Oncology

Sue Bogner  
Institute for the Study of Human Error LLC

Peggy Eastman  
Oncology Times

Nancy Carter-Foster  
DOC

Walter Ettinger  
Accretive Health

Stella Chang  
Truven Health Analytics

Linda Finkel  
Accretive Health

Chrissy Cianflone  
Duke Cancer Institute

James Flanigon  
Cancer Clinics of Excellence

Crystal Clark  
St. Francis Health System

Mark Fleury  
American Association for Cancer Research

Crawford Clay  
Colon Cancer Alliance

Ann Marie Flores  
Northeastern University

Rena Conti  
The University of Chicago

Kathleen Foley  
Truven Health

Lindsay Conway  
The Advisory Board Company

Margot Fromer  
The ASCO Post

Kristen Cox  
C-Change

Alex Fu  
Georgetown University

Janna Crittendon  
JC Consulting Group, Inc.

Vanessa Gannon  
Genentech
Matt Garabrant
The Advisory Board Company

Yola Gawlik
Amgen

Cindy Geoghegan
Patient & Partners LLC

Pamela Goetz
National Coalition for Cancer Survivorship

Elizabeth Goss
Turner & Goss LLP

Bruce Gould
Northwest Georgia Oncology Centers, P.C.

S. Orlene Grant
The Grant Group, LLC

Kristi Guillory
American Cancer Society Cancer Action Network

Kelly Haenlein
Genentech

Natalie Hamm
American Cancer Society Cancer Action Network

Michele Hanley
Catholic Health Initiatives

Erika Heaton
Genentech

Vanessa Hoffman
Bladder Cancer Advocacy Network

William Holden
Helen F. Graham Cancer Center Christiana Care Health Services

Valerie Hutchins
HillCo Health

Joseph Jacobson
Dana-Farber Cancer Institute

Patti Jewell
Pfizer

Brett Johnson
International Cancer Advocacy Network

Francis Kalush
CDRH

Sarah Karchere
Bristol Myers-Squibb

Marcia Kean
Feinstein Kean Healthcare

Roger Klein
Cleveland Clinic Foundation

Kari L. Kochenderfer
LINKAGES

Barry Kramer
National Cancer Institute

Madeline La Porta
National Cancer Institute

Ross Levine
Accretive Health

Diamond Louis
QHC

Sheila Madhani
American Society for Radiation Oncology

Jerold Mande
USDA

Hazel Manzano
Accretive Health

Jean-Claude
Marshall Catholic Health Initiatives

Dr. Mary Maryland
American Cancer Society

Michael McCaughan
The RPM Report

Amy Miller
Personalized Medicine Coalition

Kathi Mooney
University of Utah
Mark Moreno  
The University of Texas  
MD Anderson Cancer Center

Colleen Morgan  
Keiser University

Catherine Moriarty  
Axbridge

Alex Ommaya  
Department of Veterans Affairs

Kevin O’Neill  
JC Consulting Group

Scott Parker  
Northwest Georgia Oncology Centers, P.C.

Ladan Paul  
GWU

Richard Pazdur  
FDA

Douglas Peterson  
University of Connecticut  
School of Dental Medicine

Stephanie Pincus  
IOM

Bruce Quinn  
Foley Hoag LLP

Chana Rabiner  
NIH/NCI

Lydia Remington  
North American Management

Andrew Robertson  
Merck

Julian Schink  
Northwestern University

Eric Schmidt  
Accretive Health

Victor Schneider  
NASA

Ray Seigfried  
Christiana Care Health System

Mona Shah  
ACS CAN

Fay Shamanski  
College of American Pathologists

Scott Shields  
Xcenda

Pamela Farley Short  
The Pennsylvania State University

Puneet Singh  
Accretive Health

Fabrice Smeliauskas  
University of Chicago

John Sprandio  
Oncology Management Services, Inc.

Melissa Stegun  
CAP

Karen Stephenson  
Cleveland Clinic Florida

Joan Stieber  
CMS Office of Legislation

Holly Stockdale  
American Cancer Society  
Cancer Action Network

Nicole Stout  
Kaiser Permanente

Ellen Stovall  
National Coalition for Cancer Survivorship

Stephen Taplin  
National Cancer Institute

Stephanie Teleki  
California HealthCare Foundation

Cara Tenenbaum  
Ovarian Cancer National Alliance
Melanie Transparenti  
Johns Hopkins Hospital  
Weinberg Cancer Center  

Courtney Tyne  
ASCO  

Joanne Vanak  
Janssen Biotech  

Arti Varanasi  
Advancing Synergy  

Andrew Weber  
CancerCare  

Nina Wendling  
National Coalition for Cancer Survivorship  

Angele White  
Fair Chance, Inc.  

Peter Wilensky  
JC Consulting Group  

Dan Wolfson  
ABIM Foundation
Committee on Improving the Quality of Cancer Care: Addressing the Challenges of an Aging Population

Statement of Task

An Institute of Medicine committee will examine issues in the quality of cancer care with a specific focus on the demographic changes that will rapidly accelerate the number of new cancer diagnoses at a time when workforce shortages are predicted. The study will consider quality of care from the perspectives of key stakeholders, including patients, health care providers, and payors. Using other foundational IOM reports as a starting point, the committee will examine opportunities for and challenges to the delivery of high quality cancer to an aging population and formulate recommendations for improvements. The committee will:

• Review various aspects of quality cancer care, including the coordination and organization of care, outcomes reporting, quality metrics, and disparities in care,
• Consider the growing need for survivorship care, palliative care, and informal care giving,
• Consider the increasing complexity and cost of cancer care, for example through incorporation of biomarkers to predict response to therapy,
• Consider potential opportunities to improve the quality of care by aligning incentives to promote more effective models of care delivery or through specific payment reforms, and
• Consider how patients can identify, find, and access high quality cancer care.

Study Sponsors: The National Cancer Institute; Centers for Disease Control and Prevention; AARP; American Cancer Society; American College of Surgeons, Commission on Cancer; American Society of Clinical Oncology; American Society of Hematology; American Society for Radiation Oncology; LIVESTRONG; National Coalition for Cancer Survivorship; Oncology Nursing Society; and Susan G. Komen for the Cure
COMMITTEE ON IMPROVING THE QUALITY OF CANCER CARE: ADDRESSING THE CHALLENGES OF AN AGING POPULATION

COMMITTEE

PATRICIA A. GANZ, M.D. (Chair)
Professor, UCLA Schools of Medicine and Public Health
Division of Cancer Prevention & Control Research
Jonsson Comprehensive Cancer Center

MARY D. NAYLOR, PH.D., R.N., FAAN
Marian S. Ware Professor in Gerontology
Director, NewCourtland Center for Transitions and Health
University of Pennsylvania, School of Nursing

HARVEY JAY COHEN, M.D.
Walter Kempner Professor of Medicine and Director, Center for the Study of Aging and Human Development
Duke University Medical Center

LARISSA NEKHLYUDOV, M.D., M.P.H.
Clinician-investigator, Assistant Professor, Director of Cancer Research
Harvard Vanguard Medical Associates
Harvard Medical School

TIMOTHY J. EBERLEIN, M.D.
Bixby Professor and Chairman, Department of Surgery, Spencer T. and Ann W. Olin Distinguished Professor
Washington University School of Medicine

MICHAEL N. NEUSS, M.D.
Chief Medical Officer, Professor Department of Medicine
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

THOMAS W. FEELEY, M.D.
Helen Shafer Fly Distinguished Professor of Anesthesiology
Head, Division of Anesthesiology and Clinical Care
The University of Texas MD Anderson Cancer Center

NOMA L. ROBERSON, PH.D.
Cancer Research Scientist
Roswell Park Cancer Institute (Retired)

THOMAS J. SMITH, M.D.
Director and Harry J. Duffey Family Professor of Palliative Medicine and Professor of Oncology
Johns Hopkins Medicine

BETTY FERRELL, PH.D., FAAN
Professor and Research Scientist
City of Hope National Medical Center

YA-CHEN TINA SHIH, PH.D.
Associate Professor, Section of Hospital Medicine; Director, Program in the Economics of Cancer, Department of Medicine
The University of Chicago

JAMES A. HAYMAN, M.D., M.B.A.
Clinical Professor, Department of Radiation Oncology
University of Michigan
Department of Radiation Oncology

GEORGE W. SLEDGE, JR., M.D.
Professor of Medicine and Pathology and Distinguished Professor
Indiana University Simone Cancer Center

KATIE B. HORTON, J.D., M.P.H.
Research Professor
George Washington University, Department of Health Policy

THOMAS J. SMITH, M.D.
Director and Harry J. Duffey Family Professor of Palliative Medicine and Professor of Oncology
Johns Hopkins Medicine

MARY S. MCCABE, RN, MA
Director, Survivorship Program
Lecturer, Division of Medical Ethics, Weill Medical College
Memorial Sloan-Kettering Cancer Center

NEIL WENGER, M.D., M.P.H.
Professor
UCLA Department of Medicine

ARTI HURRIA, M.D.
Associate Professor; Director of the Cancer and Aging Research Program
City of Hope

Mary S. McCabe, RN, MA
Director, Survivorship Program
Lecturer, Division of Medical Ethics, Weill Medical College
Memorial Sloan-Kettering Cancer Center

NEIL WENGER, M.D., M.P.H.
Professor
UCLA Department of Medicine

Study Director:
LAURA LEVIT, JD
Program Officer
Proposed Life Cycle of "Improving the Quality of Cancer Care: Addressing the Challenges of an Aging Population"

Project Initiation
- Identify and appoint committee and consultants
- Develop Timeline

Research, Meet, Deliberate
- Hold Committee meetings and workshop
  - Meeting 1: May 21-22, 2012
  - Meeting 2: October 8, 2012 NCPF Workshop on Cost
    - October 9-10, 2012
  - Meeting 3: January 14-15, 2013
  - Meeting 4: April 8-9, 2013
- Gather data, information
- Develop draft report
- Develop consensus: conclusions & recommendations
- Report sign-off

Report Review
- Internal review
- External review
- Response to Review

Report Release, Production, and Dissemination
- Pre-pubs delivered
- Final reports printed

Dissemination
Denise R. Aberle, MD
David Geffen School of Medicine at UCLA

Dr. Denise Aberle is a Professor of Radiology and Vice Chair of Research in the UCLA Department of Radiological Sciences.

Dr. Aberle’s research interests span thoracic imaging, lung cancer, imaging-based clinical trials, and medical and imaging informatics. She was the national principal investigator of the NLST-ACRIN (National Lung Screening Trial-American College of Radiology Imaging Network), with oversight of 23 of the 33 sites and roughly 19,000 participants. The purpose of the NLST is to determine the differences in lung cancer specific mortality between low dose helical CT and chest x-ray in screening for lung cancer. Major secondary endpoints included: differences in lung cancer rates, stage at diagnosis, test performance, cost-effectiveness, and the establishment of a biorepository for the validation of early biomarkers of lung cancer.

She is deputy chair of the American College of Radiology Imaging Network (ACRIN), is a founding co-director of the UCLA Wireless Institute, and a core faculty member of the UCLA Biomedical Physics (BMP) and, Medical and Imaging Informatics (MII) programs.

Dr. Aberle has served in varying roles on many committees and her professional activities have spanned across national and international organizations. She has been awarded numerous NIH grants for research in imaging and informatics and has received awards for scientific achievement from ACRIN, the UCLA Clinical and Translational Science Institute (CTSI), the Society of Thoracic Radiology and the International Association for the Study of Lung Cancer for her leadership in oncology imaging and clinical trials.
Amy P. Abernethy, MD
Duke Cancer Institute

Amy P. Abernethy, MD, a medical oncologist, is Director of the Duke Center for Learning Health Care (CLHC) in the Duke Clinical Research Institute, and Director of the Duke Cancer Care Research Program (DCCRP) in the Duke Cancer Institute. An internationally recognized expert in health services research and delivery in patient-centered cancer care, especially pain, symptom management and palliative care, she directs a prolific research program (CLHC/DCCRP) which conducts patient-centered clinical trials, analyses, and policy studies; all CLHC/DCCRP studies make use of, and simultaneously contribute to the development of, an integrated data system that coordinates diverse datasets, leverages novel information technology for patient-reporting of symptoms and other concerns, informs future studies, and facilitates patient education and patient-provider communication. Patient reported information is central to this work.

As a part of her focus on health policy, evidence synthesis, and comparative effectiveness research, Dr. Abernethy is Co-Chair of the National Institutes of Health (NIH)-funded Palliative Care Research Cooperative Group (PCRC), an appointee to the Institute of Medicine’s National Cancer Policy Forum, President-Elect of the American Academy of Hospice & Palliative Medicine, on the Board of Directors for the Personalized Medicine Coalition, on the Advisory Board for the Rapid Learning System for Cancer of the American Society of Clinical Oncology, and she is and Co-Principal Investigator of a NIH-funded faculty development (K01) program in comparative effectiveness research at Duke. Dr. Abernethy participates integrally in current high-level national and international discussions about reforming the evidence development system, presenting a model for a rapid learning cancer clinic that coordinates clinical and research functions to better serve patients’ needs in an evidence-driven, cost-effective, and patient-centered manner.
Peter B. Bach, MD
Memorial Sloan-Kettering Cancer Center

Dr. Bach’s main research interests cover healthcare policy, particularly as relates to Medicare, racial disparities in cancer care quality, and lung cancer epidemiology. His research examining quality of care for Medicare beneficiaries has demonstrated that blacks do not receive as high quality care as whites when diagnosed with lung cancer, and that the aptitude and resources of primary care physicians who treat blacks are inferior, when compared to primary care physicians who primarily treat whites. In 2007 he was the senior author on a study demonstrating that care in Medicare is highly fragmented, with the average beneficiary seeing multiple primary care physicians and specialists. His work in lung cancer epidemiology has focused on the development and utilization of lung cancer prediction models that can be used to determine what lung cancer events populations of elderly smokers will experience over a period of time. His healthcare policy analysis includes investigations into Medicare’s approaches to cancer payment, as well as developing models of alternative reimbursement, payment systems, and coverage policies. He is funded by grants from the National Institute of Aging, a contract from the NCI, and philanthropic sources. He formerly served a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services. He serves on several national committees, including the Institute of Medicine’s National Cancer Policy Forum, and the Committee on Performance Measurement of the National Committee on Quality Assurance. He chairs the Technical Expert Panel that is developing measures of cancer care quality for CMS. Along with publishing in the medical literature, Dr. Bach’s opinion pieces have appeared in numerous lay new outlets, including the New York Times, the Wall Street Journal, Forbes Online and National Public Radio.
Justin E. Bekelman, MD
University of Pennsylvania

Dr. Bekelman is Assistant Professor of Radiation Oncology, Member of the Abramson Cancer Center, Associate Scholar in the Center for Clinical Epidemiology and Biostatistics, and Senior Fellow at the Leonard Davis Institute for Health Economics at the University of Pennsylvania Perelman School of Medicine. He conducts cancer health services and comparative effectiveness research, with a particular focus on treatments for urologic cancers and the adoption and diffusion of advanced radiotherapy technologies. Dr. Bekelman's research employs both randomized and non-randomized study designs to develop a body of comparative evidence about cancer treatments that incorporates both approaches and acknowledges their value and limitations. His current projects investigate the comparative effectiveness of radiotherapy for men with prostate cancer, including conducting observational studies to examine the heterogeneity of treatment effects in older adults and a multi-center randomized trial to compare proton therapy to intensity-modulated radiotherapy (IMRT). Dr. Bekelman serves on the Executive Committee of the National Radiation Oncology Registry, sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiation Oncology Institute (ROI). Dr. Bekelman has been funded by research grants from the National Cancer Institute, the American Cancer Society, and philanthropic sources. Dr. Bekelman's clinical practice focuses on the treatment of men with prostate cancer and other urologic malignancies.
Otis Webb Brawley, MD, FACP
American Cancer Society

As the chief medical and scientific officer and executive vice president of the American Cancer Society, Otis Webb Brawley, MD, is responsible for promoting the goals of cancer prevention, early detection, and quality treatment through cancer research and education. He champions efforts to decrease smoking, improve diet, detect cancer at the earliest stage, and provide the critical support cancer patients need. He also guides efforts to enhance and focus the research program, upgrade the Society’s advocacy capacity, and concentrate community cancer control efforts in areas where they will be most effective. Further, as an acknowledged global leader in the field of health disparities research, Dr. Brawley is a key leader in the Society’s work to eliminate disparities in access to quality cancer care.

Dr. Brawley currently serves as professor of hematology, oncology, medicine and epidemiology at Emory University. He is also a medical consultant to the Cable News Network (CNN). From April of 2001 to November of 2007, he was medical director of the Georgia Cancer Center for Excellence at Grady Memorial Hospital in Atlanta, and deputy director for cancer control at the Winship Cancer Institute at Emory University. He has also previously served as a member of the Society’s Prostate Cancer Committee, co-chaired the U.S. Surgeon General’s Task Force on Cancer Health Disparities, and filled a variety of positions at the National Cancer Institute (NCI), most recently serving as Assistant Director.

Currently, Dr. Brawley is a member of the Centers for Disease Control and Prevention Advisory Committee on Breast Cancer in Young Women. He was a member of the Centers for Disease Control and Prevention Breast and Cervical Cancer Early Detection and Control Advisory Committee. He served as a member of the Food and Drug Administration Oncologic Drug Advisory Committee and Chaired the NIH Consensus Panel on the Treatment of Sickle Cell Disease.

He is listed by Castle Connell as one of America’s Top Doctors for Cancer. Among numerous other awards, he was a Georgia Cancer Coalition Scholar and received the Key to St. Bernard Parish for his work in the U.S. Public Health Service in the aftermath of Hurricane Katrina.

Dr. Brawley is a graduate of University of Chicago, Pritzker School of Medicine. He completed a residency in internal medicine at University Hospitals of Cleveland, Case-Western Reserve University, and a fellowship in medical oncology at the National Cancer Institute.
Renzo Canetta, MD
Bristol-Myers Squibb Company

Dr. Renzo Canetta is Vice President of Oncology Global Clinical Research at Bristol-Myers Squibb.

CAREER
During his early years at the Istituto Nazionale Tumori in Milan, Italy (1974-1980), Dr. Canetta’s focus was on clinical trials in lymphomas and gastrointestinal tumors, among others. Since joining Bristol-Myers Squibb (BMS) in 1980, Dr. Canetta has held numerous roles of increasing responsibility and leadership, including head of clinical cancer research; head of development, life cycle management; and, currently, as vice president, oncology global clinical research. His experience can be summarized with the introduction of 17 new BMS chemical entities and the approval of over 50 regulatory dossiers for additional indications/formulations, including some outside of oncology.

EDUCATION
Universita' degli Studi, Milan, Italy. Graduate, Medicine and Surgery (M.D.), 1976
Istituto Nazionale Tumori, Milan, Italy. State Certification, Clinical Oncology, 1977
Universita' degli Studi, Milan, Italy. Board Certification, Clinical and Laboratory Hematology, 1979.

AREA OF EXPERTISE
Cancer patient care, diagnosis and experimental treatment of hematologic malignancies and solid tumors, methodology of clinical trials, and new drug development.
Susan Dentzer
Health Affairs

Susan Dentzer is the editor-in-chief of Health Affairs, the nation’s leading peer-reviewed journal focused on the intersection of health, health care and health policy in the United States and internationally. One of the nation’s most respected health and health policy journalists, she is an on-air analyst on health issues with the PBS NewsHour, and a frequent guest and commentator on such National Public Radio shows as This American Life and The Diane Rehm Show.

Dentzer is an elected member of the Institute of Medicine, the health arm of the National Academy of Sciences, and of the Council on Foreign Relations, the independent, nonpartisan membership organization and think tank dedicated to exploring the foreign policy choices facing the United States and other countries.

At Health Affairs, Dentzer oversees the journal’s team of nearly 30 editors and other staff in producing the monthly publication and web site. Health Affairs has been described by the Washington Post as the “Bible” of health policy. Its articles and their authors are frequently cited in the Congressional Record and in congressional testimony as well as in the news media. The Health Affairs web site recorded 50 million page views in 2010.

Before joining Health Affairs in May 2008, Dentzer was on-air Health Correspondent at the PBS NewsHour. From 1998 to 2008, she led the show’s unit providing in-depth coverage of health care and health policy. Prior to joining the PBS NewsHour, she was chief economics correspondent and economics columnist for U.S. News & World Report, and previously was a senior writer at Newsweek.

Dentzer’s other work in television has included appearances as a regular analyst or commentator on CNN and The McLaughlin Group. Her writing has also earned her several fellowships, including a Nieman Fellowship at Harvard University, where she studied health economics and policy, and a U.S.-Japan Leadership Program Fellowship, during which she researched the effects of the rapidly aging Japanese population.

Dentzer is an elected member of the National Academy of Social Insurance, a nonprofit, nonpartisan organization made up of the nation’s leading experts on social insurance, is a fellow of the Hastings Center, a nonpartisan research institution dedicated to bioethics and the public interest.

Dentzer is a member of the Board of Directors of Research!America, the nation’s largest not-for-profit public education and advocacy alliance committed to making research to improve health a higher national priority. She is also a member of the Board of Overseers of the International Rescue Committee, a humanitarian organization providing relief to refugees and displaced persons around the world. She chairs the IRC board’s Program Committee, which oversees the organization’s activities in resettling refugees in the United States and in dealing with refugees.
and displaced persons in roughly 25 countries. Formerly, Dentzer served on the Board of Directors of the Global Health Council and was its chair from 2008-2010.

A graduate of Dartmouth and holder of an honorary master of arts from the institution, Ms. Dentzer is a Dartmouth trustee emerita and chaired the Dartmouth Board of Trustees from 2001 to 2004. She serves on the Board of Overseers of Dartmouth Medical School.

Dentzer, her husband and their three children live in the Washington, DC area.
Craig Earle, MD, MSc, FRCPC  
Ontario Institute for Cancer Research  

Dr. Craig Earle is a medical oncologist at Sunnybrook’s Odette Cancer Centre in Toronto, Canada, a Professor of Medicine at the University of Toronto, a Senior Scientist at the Institute for Clinical Evaluative Sciences, and the Director of Health Services Research for Cancer Care Ontario and the Ontario Institute for Cancer Research. Prior to the summer of 2008, he spent 10 years in Boston at Harvard Medical School and the Harvard School of Public Health. While there, he was the founding Director of the Lance Armstrong Foundation Adult Survivorship Clinic at Dana-Farber Cancer Institute. His personal research interests focus on evaluating and improving the quality of care received by patients with advanced cancer and cancer survivors.
Dr. Eisenberg has been in the private practice of medical oncology in Marin County for almost 35 years. He was a founding member of the Association of Northern California Oncologists and its first President. He was a member of the American Society of Clinical Oncology’s Board of Directors. He has a great interest in quality metrics in oncology and the development of tools to enable practitioners to provide such care. He was a founding member of ASCO’s Quality Oncology Practice Initiative.

He has a strong commitment to clinical research and his practice, Marin Specialty Care, has been a leader in the movement of clinical trials from the University to the community.

He lives and practices just north of San Francisco, enjoys the company of his wife and three girls and rides his bike to work.
Ezekiel J. Emanuel, MD, PhD
University of Pennsylvania

Ezekiel J. Emanuel is the Vice Provost for Global Initiatives, the Diane v.S. Levy and Robert M. Levy University Professor, and Chair of the Department of Medical Ethics and Health Policy at the University of Pennsylvania.

He was the founding chair of the Department of Bioethics at the National Institutes of Health and held that position until August of 2011. Until January 2011, he served as a Special Advisor on Health Policy to the Director of the Office of Management and Budget and National Economic Council. He is also a breast oncologist and author.

After completing Amherst College, he received his M.Sc. from Oxford University in Biochemistry. He received his M.D. from Harvard Medical School and his Ph.D. in political philosophy from Harvard University. In 1987-88, he was a fellow in the Program in Ethics and the Professions at the Kennedy School of Government at Harvard.

After completing his internship and residency in internal medicine at Boston’s Beth Israel Hospital and his oncology fellowship at the Dana-Farber Cancer Institute, he joined the faculty at the Dana-Farber Cancer Institute.

Dr. Emanuel’s publications include The Oxford Textbook of Clinical Research Ethics, edited by Dr. Emanuel and members of the NIH Department of Bioethics and Healthcare, Guaranteed, Dr. Emanuel’s own recommendations for health care reform and, Exploitation and Developing Countries. He is also an Op-Ed contributor to the New York Times. He has published widely on the ethics of clinical research, health care reform, international research ethics, end of life care issues, euthanasia, the ethics of managed care, and the physician-patient relationship in the New England Journal of Medicine, the Lancet, JAMA, and many other medical journals.

He has received numerous awards including election to the Institute of Medicine (IOM) of the National Academy of Science, the Association of American Physicians, and the Royal College of Medicine (UK). Hippocrates Magazine selected him as Doctor of the Year in Ethics. He received the AMA-Burroughs Welcome Leadership Award, the Public Service Award from the American Society of Clinical Oncology, the John Mendelsohn Award from the MD Anderson Cancer Center, and a Fulbright Scholarship (which he declined).

Dr. Emanuel served on President Clinton’s Health Care Task Force, the National Bioethics Advisory Commission (NBAC), and on the bioethics panel of the Pan-American Healthcare Organization.
Robert L. Erwin, MS
Marti Nelson Cancer Foundation

Cancer Patient Advocacy
Robert Erwin co-founded the not-for-profit Marti Nelson Cancer Foundation in 1994 with his late wife, Marti Nelson, M.D. This advocacy organization, based in Davis, California, provides free assistance to patients seeking help with clinical trial enrollment or other access to experimental therapies. The organization operates through a network of unpaid, ad hoc volunteers, including scientists, physicians, and people with other relevant expertise. The Foundation’s website, www.CancerActionNow.org has become a resource for individuals looking for additional information on a variety of cancer-related topics. During the past few years, the Foundation has broadened its services to include provision of technical information and analysis to other advocacy organizations, and has increased its work on complex or controversial policy issues in drug development, approval and reimbursement that affect groups of patients as well as individuals.

Mr. Erwin is also a member of the board of directors of C3: The Colorectal Cancer Coalition (Alexandria, Virginia), and the NorthBay Healthcare Foundation (Fairfield, California). Mr. Erwin serves as a member of the Data and Safety Monitoring Board for the Cancer and Leukemia Group B. He is a member of the Research Committee of the American Society of Clinical Oncology, and a member of the National Cancer Policy Forum. He served as member of the California Breast Cancer Research Council from 1996 to 1999 and was its Chairman from 1997 to 1999.

Commercial Biotechnology
Mr. Erwin is President of iBioPharma, Inc. (Newark, Delaware), a public biotechnology company developing vaccines for the prevention and treatment of infectious diseases. He is also chairman of Novici Biotech LLC (Vacaville, California). From 2003 until 2007 he was managing director of Bio-Strategic Directors LLC, a life science-industry consulting firm focused on intellectual property and strategy. He was chief executive officer of Large Scale Biology Corporation from 1992 to 2003 and served as its chairman until 2006. He was chairman of Icon Genetics AG from 1999 until its acquisition by a subsidiary of Bayer AG in 2006.

Mr. Erwin is an inventor on several issued and pending patents. He has B.S. and M.S. degrees in zoology and genetics from Louisiana State University.
Harvey V. Fineberg, MD, PhD
Institute of Medicine

Harvey V. Fineberg is President of the Institute of Medicine. He served as Provost of Harvard University from 1997 to 2001, following thirteen years as Dean of the Harvard School of Public Health. He has devoted most of his academic career to the fields of health policy and medical decision making. His past research has focused on the process of policy development and implementation, assessment of medical technology, evaluation and use of vaccines, and dissemination of medical innovations.

Dr. Fineberg helped found and served as president of the Society for Medical Decision Making and also served as consultant to the World Health Organization. At the Institute of Medicine, he has chaired and served on a number of panels dealing with health policy issues, ranging from AIDS to new medical technology. He also served as a member of the Public Health Council of Massachusetts (1976-1979), as chairman of the Health Care Technology Study Section of the National Center for Health Services Research (1982-1985), and as president of the Association of Schools of Public Health (1995-1996).

Dr. Fineberg is co-author of the books Clinical Decision Analysis, Innovators in Physician Education, and The Swine Flu Affair, an analysis of the controversial federal immunization program against swine flu in 1976. He has co-edited several books on such diverse topics as AIDS prevention, vaccine safety, and understanding risk in society. He has also authored numerous articles published in professional journals. Dr. Fineberg is the recipient of several honorary degrees and the Joseph W. Mountin Prize from the US Centers for Disease Control. He earned his bachelor's and doctoral degrees from Harvard University.
Patricia A. Ganz, MD  
University of California, Los Angeles  

Dr. Patricia A. Ganz is Professor of Medicine at the David Geffen School of Medicine and Professor of Health Policy & Management at the Jonathan and Karin Fielding School of Public Health at UCLA. 

Dr. Ganz, a medical oncologist, has been a member of the faculty of the UCLA School of Medicine since 1978 and the UCLA School of Public Health since 1992. Since 1993, she has been the Director of Cancer Prevention and Control Research at the Jonsson Comprehensive Cancer Center. In 1999, she was awarded an American Cancer Society Clinical Research Professorship for “Enhancing Patient Outcomes across the Cancer Control Continuum.” Dr. Ganz was elected to the Institute of Medicine in 2007. She served on the National Cancer Institute Board of Scientific Advisors from 2002-2007 and on the American Society of Clinical Oncology (ASCO) Board of Directors from 2003-2006. She received the American Cancer Society Medal of Honor in 2010. Dr. Ganz is a pioneer in the assessment of quality of life in cancer patients, and has focused much of her clinical and research efforts in the areas of breast cancer and its prevention. At the Jonsson Comprehensive Cancer Center, she leads the scientific program focused on Patients and Survivors. Her major areas of research include cancer survivorship and late effects of cancer treatment, cancer in the elderly, and quality of care for cancer patients. Dr. Ganz currently serves as Vice Chair of the Institute of Medicine National Cancer Policy Forum.
James S. Goodwin, MD
University of Texas Medical Branch

Dr. James S. Goodwin is the George and Cynthia Mitchell Distinguished Chair in Geriatric Medicine at UTMB, and is Director of the Sealy Center on Aging: www.utmb.edu/scoa

Dr. Goodwin received his baccalaureate degree from Amherst College and his medical degree from Harvard Medical School. Starting in the mid 1980’s, he studied patterns of diagnosis, treatment and outcomes of cancer in the elderly, using population-based interview studies as well as analyses of administrative databases. More recently he has used national Medicare data to evaluate overutilization of tests and treatments.

Dr. Goodwin has developed and directed several multidisciplinary research centers. At UTMB, these include the Claude Pepper Older Americans Independence Center and the Center for Population Health and Health Disparities. Dr. Goodwin is listed in “Best Doctors” in America. His 300 research articles have been cited more than 15,000 times in the scientific literature.
Robert J. Green, MD, MSCE
Palm Beach Cancer Institute

Dr. Robert Green is a medical oncologist and the Chief Medical Officer of Cancer Clinics of Excellence (CCE). CCE is the nation’s largest independent network of physician-driven community based medical oncology practices. Comprised of over 200 oncologists at 87 sites throughout the United States, CCE was founded in 2007 to integrate evidence-based protocols into the community oncology setting, ensuring quality care while controlling costs. Continuing to provide a differential for its member practices, CCE is now fully integrating molecular diagnostic testing into cancer care, and developing a novel, molecularly directed, clinical trial initiative. CCE has recently embarked in a cooperative relationship with Accretive Health to develop a high quality, more affordable care management model for community oncology.

Dr. Green continues to practice oncology and serves as managing partner at the Palm Beach Cancer Institute (PBCI) in Palm Beach County, Florida, a multispecialty oncology group, providing care to over 3000 new patients annually. He has a particular clinical interest in thoracic and gastrointestinal malignancies and is co-director of PBCI’s multidisciplinary thoracic clinic.

Dr. Green received his undergraduate and medical degrees from Duke University. He completed a Masters in Clinical Science and Epidemiology at the University of Pennsylvania where he also completed his internship and residency in internal medicine, and his fellowship in medical oncology.
Jessie Gruman, PhD
Center for Advancing Health

Jessie Gruman is president of the Center for Advancing Health, a nonpartisan, Washington-based policy institute founded in 1992 and supported by foundations and individuals to work on patient engagement: people will not benefit from the health care available to them unless they can participate fully and competently in it. Dr. Gruman draws on her own experience of treatment for four cancer diagnoses, surveys, peer-reviewed research and interviews with patients and caregivers as the basis of her work to describe — and advocate for policies and practices to overcome — the challenges people face in finding good care and getting the most from it.

Dr. Gruman has worked on this same set of concerns in the private sector (AT&T), the public sector (National Cancer Institute) and the voluntary health sector (American Cancer Society). She holds a B.A. from Vassar College and a Ph.D. in Social Psychology from Columbia University and is a Professorial Lecturer in the School of Public Health and Health Services at The George Washington University. She serves on the board of trustees of the Center for Medical Technology Policy and the Technical Board of the Milbank Memorial Fund.

Dr. Gruman was honored by Research!America for her leadership in advocacy for health research and received honorary doctorates from Brown University, Carnegie Mellon University, Clark University, Georgetown University, New York University, Northeastern University, Salve Regina University, Syracuse University and Tulane University, and the Presidential Medal of The George Washington University. She is a fellow of the Society for Behavioral Medicine and a member of the American Academy of Arts and Sciences, the Council on Foreign Relations and the New York Academy of Medicine.

Dr. Gruman is the author of The Experience of the American Patient: Risk, Trust and Choice (Health Behavior Media, 2009); Behavior Matters (Health Behavior Media, 2008) and AfterShock: What to Do When the Doctor Gives You — or Someone You Love — a Devastating Diagnosis (Walker Publishing, second edition, 2010), as well as scientific papers and opinion essays and articles.
Jim C. Hu, MD, MPH  
University of California, Los Angeles

Dr. Jim Hu is a urologist whose research and clinical interests focus on prostate cancer. Prostate cancer is the most commonly diagnosed malignancy with a lifetime prevalence of 1 out of 6 in the United States. Dr. Hu did his urologic surgical residency at UCLA and also trained in a health services research fellowship at the UCLA Jonsson Cancer Center with Mark Litwin, MD, MPH. He published a paper in the *Journal of Clinical Oncology*, which also received press in the *Boston Globe*, assessing the impact of radical prostatectomy surgeon volume on outcomes. This paper is cited as empirical evidence by the state of Massachusetts in an initiative to make healthcare more transparent, control costs, and improve quality of care. It is referenced online at mass.gov, where statewide hospital and surgeon radical prostatectomy volumes are posted in an effort to drive patients to the lowest-cost, highest-quality providers. More recently, he published another paper in the *Journal of Clinical Oncology* illustrating the consequences of rapid adoption of laparoscopic radical prostatectomy with or without robotic assistance and the increased risk of suboptimal cancer control and postoperative strictures for men undergoing laparoscopic radical prostatectomy with low volume surgeons. This was cited in both the *New York Times* and the *Washington Post*.

Dr. Hu's scholarly activity has been recognized and funded by both private foundations and federal sources. He was awarded a Dana Farber/Harvard Cancer Center prostate cancer SPORE career development award, and he is the recipient of the Lance Armstrong Young Investigator award to assess the efficacy and complications of treatments for localized prostate cancer. Moreover, he was awarded a Department of Defense Prostate Cancer Physician Training Award. The body of these research efforts will focus on improving the quality of care for men with prostate cancer and correlate the sensitivity of RAND prostate cancer quality indicators with good outcomes. The ideal research population for assessing this hypothesis will be community based. The data must be collected prospectively, which is very costly and time intensive. Thus, Dr. Hu is reaching out to philanthropy to support this important and timely research endeavor.

In addition to research interests, Dr. Hu is also one of the highest volume radical prostatectomy surgeons in New England. He has performed more than 475 radical prostatectomies over the last 3 years. He recently published a clinical paper describing landmarks for consistent nerve-sparing to improve sexual function postoperatively. Another research front for Dr. Hu encompasses improving radical prostatectomy surgical technique and outcomes. He is presently working with the Department of Radiology and Pathology to map the course of the neurovascular bundles in relation to the prostate and areas of cancer. The goal is to compare imaging from 3 Tesla MRI’s with the radical prostatectomy specimen; however, the specimen must be whole mounted, a very costly and
time-consuming process which presently is not being done at the Brigham. Therefore, philanthropic support is sought to support this project, which may ultimately improve cancer control and quality of life following surgery.

Dr. Hu joined the UCLA urology faculty in April 2012 as professor and Henry E. Singleton Chair in Urology, director of minimally invasive urology, co-director of the UCLA Center for Advanced Surgical and Interventional Technology, and director of the Urology Procedures Unit.
Tom Kean, MPH  
C-Change

Tom Kean has devoted more than 35 years of his career to chronic disease prevention and control. He has served government, not-for-profit and for profit institutions in progressively responsible positions as a health educator, evaluator and senior manager/administrator. His assignments have included the University of Texas System Cancer Center, the National Cancer Institute, and the AMC Cancer Research Center. In 1994, he co-founded Strategic Health Concepts, a Colorado based consulting company, to help health organizations better achieve their goals through sound planning and management combined with solid technical capacity. In 2006, Tom became the Executive Director of C-Change, a coalition of leaders from organizations representing the public, private and voluntary sectors devoted to eliminating the burden of cancer on the US population. In addition to his professional activities, Tom has been actively involved over the years in volunteer work with community groups for public school education, cancer control and tobacco use prevention. In 1986, he was awarded the NIH Award of Merit for his contributions in cancer prevention and control. In 1993, he received the National Cancer Institute’s Marion Morra Award for his contributions in cancer communications. In 2009, he received the Distinguished Visionary Leader in Medicine award from the Life Beyond Cancer Foundation.
Dr. Barnett S. Kramer, MD, MPH
National Cancer Institute

Dr. Kramer is the Director of the Division of Cancer Prevention at the National Cancer Institute. He was Editor-in-Chief of the Journal of the National Cancer Institute from 1994 to 2012. He serves as Chairman of the Physician Data Query (PDQ) Editorial Board on Screening and Prevention and is a member of the PDQ Treatment Editorial Board. Dr. Kramer has served on the Cancer Prevention Committee of the American Society of Clinical Oncology (ASCO) and was the committee chairperson from 2006 to 2007.

Dr. Kramer received his medical degree from the University of Maryland Medical School, and completed his internship and residency in internal medicine at Barnes Hospital in St. Louis, Missouri. He completed a medical oncology fellowship at the National Cancer Institute (U.S.). He is board-certified in internal medicine and medical oncology, and has received a master’s degree in public health from Johns Hopkins University Bloomberg School of Public Health.

Dr. Kramer has extensive experience in primary cancer prevention studies, as well as clinical screening trials of lung, ovarian, breast and prostate cancers. He is an investigator and on the steering committee for two large cancer screening trials sponsored by the National Cancer Institute: the Prostate, Lung, Colorectal, Ovarian (PLCO) Trial; and the National Lung Screening Trial (NLST). He has a strong interest in weighing and reporting the strength of medical evidence and created an annual Medicine in the Media Workshop to help working journalists develop methods of reporting medical evidence.
Dr. Allen S. Lichter is the Chief Executive Officer (CEO) of the American Society of Clinical Oncology (ASCO), the world’s leading professional organization representing nearly 30,000 physicians and health professionals in oncology.

Prior to joining ASCO in 2006, Dr. Lichter was at the University of Michigan in two significant leadership roles. He served as Chair and Professor of Radiation Oncology from 1984-1998 and as Dean of the Medical School from 1998 - 2006. Dr. Lichter was named the first Isadore Lampe Professor of Radiation Oncology, an endowed chair, and also was the Newman Family Professor of Radiation Oncology.

Prior to his tenure at the University of Michigan, Dr. Lichter was the Director of the Radiation Therapy Section of the NCI’s Radiation Oncology Branch. Dr. Lichter’s research and development of three-dimensional treatment planning led to a Gold Medal from the American Society for Therapeutic Radiology and Oncology (ASTRO). In 2002 he was elected to membership in the Institute of Medicine of the National Academies of Science.

As a member of ASCO since 1980, Dr. Lichter has assumed many prominent roles in the Society, including President (1998-1999) and Founding Chairman of ASCO’s Conquer Cancer Foundation Board.

Dr. Lichter earned a bachelor’s degree (1968) and medical degree (1972) from the University of Michigan. He trained in radiation oncology at University of California, San Francisco, before joining the faculty at Johns Hopkins University, and later the National Cancer Institute.
Mark B. McClellan, MD, PhD
The Brookings Institution

Dr. Mark McClellan is senior fellow, director of the Engelberg Center for Health Care Reform, and Leonard D. Schaeffer Chair in Health Policy Studies at the Brookings Institution. Established in 2007, the Engelberg Center provides practical solutions to achieve high-quality, innovative, affordable health care with particular emphasis on identifying opportunities on the national, state and local levels.

A doctor and economist by training, McClellan has a highly distinguished record in public service and academic research. He is a former administrator of the Centers for Medicare & Medicaid Services (CMS) and former commissioner of the Food and Drug Administration (FDA). He also served as a member of the President’s Council of Economic Advisers and senior director for health care policy at the White House. In these positions, he developed and implemented major reforms in health policy, including:

- The Medicare prescription drug benefit and other innovative coverage options, including the move from indemnity insurance to personalized, prevention-oriented care;
- Innovative approaches to coverage in Medicaid and the State Children’s Health Insurance Program, including roadmaps that states have used to update and expand coverage and the “Money Follows the Person” initiatives in long-term care;
- The development of the FDA’s Critical Path initiative, regulatory reforms to modernize pharmaceutical manufacturing, efficient risk-management methods to better address safety issues, and reforms to speed the approval of low-cost generic medicines and improve the availability of safe effective treatments; and
- Public-private initiatives to develop better information on the quality and cost of care, and steps to help consumers and providers use this information to improve care, including performance-based provider payment reforms, Health Savings Accounts and Health Reimbursement Arrangements.

Previously, McClellan served in the Clinton administration as deputy assistant secretary of the Treasury for economic policy, where he supervised economic analysis and policy development on a range of domestic policy issues.

McClellan also served as an associate professor of economics and associate professor of medicine with tenure at Stanford University, where he directed Stanford’s Program on Health Outcomes Research; was associate editor of the Journal of Health Economics; and co-principal investigator of the Health and Retirement Study (HRS), a longitudinal study of the health and economic status of older Americans. He has twice received the Kenneth J. Arrow Award for Outstanding Research in Health Economics.
From time to time, McClellan advises U.S. government officials on health care policy issues. In his capacity as a health policy expert, he is the co-director of the Bipartisan Policy Center's Leaders' Project on the State of American Health Care; co-chair of the Robert Wood Johnson Foundation Commission to Build a Healthier America; and chair of the FDA's Reagan-Udall Foundation. McClellan is also co-chair of the Quality Alliance Steering Committee, sits on the National Quality Forum's Board of Directors, is a member of the Institute of Medicine of the National Academy of Sciences, and is a research associate at the National Bureau of Economic Research.

McClellan holds an MD from the Harvard University–Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology, a PhD in economics from MIT, an MPA from Harvard University, and a BA from the University of Texas at Austin. He completed his residency training in internal medicine at Boston’s Brigham and Women's Hospital, is board-certified in Internal Medicine, and has been a practicing internist during his career.
John Mendelsohn, MD, was president of The University of Texas MD Anderson Cancer Center in Houston from 1996 until 2011. Under his direction, MD Anderson assumed a leadership role in translational and clinical cancer research, and was named the top cancer hospital in the United States eight of the past ten years in U.S. News & World Report's “America's Best Hospitals” survey. Currently, Dr. Mendelsohn is the director of the Khalifa Institute for Personalized Cancer Therapy at MD Anderson. Previously, he chaired the Department of Medicine at Memorial Sloan-Kettering Cancer Center, and he began his career at UCSD in La Jolla, where he was founding director of its cancer center. Dr. Mendelsohn and his collaborators pioneered the concept of therapy targeting the products of genes that cause cancer. His team's innovative research on inhibition of the EGF receptor tyrosine kinase led to production and investigation of monoclonal antibody C225 (Erbitux), which is FDA-approved for colon cancer and head and neck cancer. He served as founding editor-in-chief of Clinical Cancer Research, has published over 250 articles and reviews, and has received many prizes and awards. Dr. Mendelsohn is chair of the Institute of Medicine’s National Cancer Policy Forum. He has directed postdoctoral programs which trained many dozens of medical oncologists and scientists. He is an active board member of several Houston-area organizations, including Houston Grand Opera, the BioHouston and the Center for Houston’s Future.
Dr. Therese Mulvey has dedicated her career to providing state-of-the-art, community-based care for cancer patients. As Physician-In-Chief for the Southcoast Centers for Cancer Care, Dr. Mulvey oversees programs that are committed to ensuring patients have access to high-quality oncology services and leading-edge clinical cancer research. Dr. Mulvey earned her medical degree at Tufts University School of Medicine. She completed fellowships in hematology/oncology at Massachusetts General Hospital as well as Tufts-New England Medical Center, where she also completed her residency. She has trained extensively in cancer genetics and specializes in hereditary cancer syndromes and cancer risk assessment. Dr. Mulvey is board certified in medical oncology and internal medicine.
Lee N. Newcomer, MD, MHA
UnitedHealthcare

Lee N. Newcomer, MD, MHA, is the Senior Vice President, Oncology for UnitedHealthcare. His unit is responsible for improving the quality and affordability of care for the 111,000 cancer patients covered by United Healthcare.

Prior to rejoining United Health Group (UHG), Dr. Newcomer was a founding executive of Vivius, a consumer directed venture that allowed consumers to create their own personalized health plans. From 1991 to 2000, Dr. Newcomer held a number of positions at UHG, including Chief Medical Officer. His work there emphasized the development of performance measures and incentives to improve clinical care. Prior to joining UHG, he was Medical Director for CIGNA Health Care of Kansas City.

Dr. Newcomer is a board certified medical oncologist; he practiced medical oncology for nine years in Tulsa, Oklahoma and Minneapolis (Park Nicollet Clinic).

He is currently the Chairman of Park Nicollet Health Services, an integrated system of over 650 physicians and a 400 bed hospital. The group is nationally recognized for its leadership in quality, safety and lean processes.

Dr. Newcomer earned a Bachelor of Arts degree in biology from Nebraska Wesleyan University, an MD degree from the University of Nebraska College of Medicine, and an MS degree in health administration from the University of Wisconsin at Madison. He completed his internship and residency in internal medicine from the University of Nebraska Hospital, and fellowships in medical oncology and administrative medicine from the Yale University School of Medicine and the University of Wisconsin at Madison, respectively.
Jeffrey Peppercorn, MD, MPH
Duke University

Dr. Jeffrey Peppercorn is a hematologist/oncologist with special interests in breast cancer, medical ethics, and health care policy. He trained at Harvard Medical School, completed internal medicine residency at Massachusetts General Hospital, and completed his hematology/oncology fellowship training at the Dana-Farber Cancer Institute. He also completed the Harvard Medical School fellowship in bioethics and obtained his MPH from Harvard. He is currently an Associate Professor of Medicine at Duke University in the division of Medical Oncology and Faculty Associate of the Trent Center for Bioethics at Duke. He serves as chair of the CALGB oncology cooperative group ethics committee and chair elect of the ASCO Ethics committee and a member of the ASCO Education Committee, Clinical Practice Guidelines Committee and Taskforce on Cost of Cancer Care. His research ranges from clinical trials of novel therapeutics for breast cancer to issues related to medical ethics and health policy, with a focus on the intersection between clinical care and clinical research in oncology. He is a Greenwall Foundation Faculty Scholar in Bioethics.
Scott Ramsey, MD, PhD
Fred Hutchinson Cancer Research Center
Institute for Cancer Outcomes Research and Evaluation

Scott Ramsey, MD, PhD, is a Full Member in the Cancer Prevention Program at the Fred Hutchinson Cancer Research Center where he directs the Research and Economic Assessment in Cancer and Healthcare (REACH) group, a multidisciplinary team devoted to clinical and economic evaluations of new and existing cancer prevention, screening and treatment technologies. He is also a Professor in the School of Medicine, School of Pharmacy, and Institute for Public Health Genetics at University of Washington. Trained in Medicine and economics, his primary research interest is in studying the economic aspects of new medical technologies. Dr. Ramsey is a leader in the field of Comparative Effectiveness Research (CER), past President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the IOM National Cancer Policy Forum.
Lowell E. Schnipper, MD
Beth Israel Deaconess Medical Center

Dr. Lowell Schnipper is the Theodore W. and Evelyn G. Berenson Professor in the Department of Medicine at the Harvard Medical School. He is also clinical director of the Beth Israel Deaconess Medical Center Cancer Center, and is chief of its Division of Hematology/Oncology.

Schnipper received his M.D. from the State University of New York Downstate College of Medicine, summa cum laude, and trained at the Yale New Haven Medical Center, the National Cancer Institute, and Washington University. In addition to his clinical work and teaching, Schnipper is deeply committed to oncology research, receiving numerous grants over the years from the National Cancer Institute and American Cancer Society, and publishing more than 120 papers on subjects ranging from developing new anti-viral and anti-cancer therapies, to the basic biology of cancer, to ethical issues in cancer research.

He has built a program boasting 65 faculty physicians and scientists whose mutual goal is to achieve clinical excellence through scientific understanding of cancer coupled with personalized care. Among the unique initiatives that have come about under his leadership is a molecular imaging program aimed at identifying cancer at its most minimal stage, a research program on the origins of leukemia, and translational research in tumor vaccines and prostate cancer.

Areas of long-term research interest include genomic instability of malignant neoplasms, the basis of resistance and sensitivity to inhibitors of topoisomerase II, the efficacy of high-dose chemotherapy and autologous stem cell reinfusion as a novel therapy for a range of advanced solid tumors, and developmental therapeutics.

Schnipper has been a member of the board of directors of the American Cancer Society and president of its Massachusetts Division. He is the recipient of the St. George Medal from the American Cancer Society and a Distinguished Public Service Award from the American Society of Clinical Oncology. He has also held a number of leadership positions in the American Society of Clinical Oncology, including chair of the Ethics Committee that updated the Society’s policy on conflict of interest. Most recently, Schnipper has chaired ASCO’s Cancer Research Committee, and since 2008 he has led that society’s Task Force on the Cost of Cancer Care. This initiative has led to defining clinical scenarios in which the quality of care can be improved and costs contained by using available high quality evidence as a guide. Boston Magazine has voted him one of Boston’s top oncologists four times, and he is listed in Best Doctors of America.
Joanne Schottinger, MD
Kaiser Permanente Care Management Institute

Dr. Joanne Schottinger is a medical oncologist who is a graduate of the Boston University School of Medicine and trained in hematology/oncology at the University of California, Irvine. Currently she is the national clinical lead for cancer for the Kaiser Permanente Care Management Institute. In the Southern California Permanente Medical Group, she oversees the cancer program, new technology assessment, clinical practice guidelines, and lab/radiology utilization.
Dr. Deborah Schrag is a health services researcher and medical oncologist at the Dana-Farber Cancer Institute. She is an Associate Professor of Medicine at Harvard Medical School and an Attending Physician at the Dana-Farber Cancer Institute. She is the current Deputy Associate Director of Population Sciences at Dana-Farber / Harvard Cancer Center. She received an MD from Columbia University and an M.P.H. from Harvard School of Public Health. Before working at Harvard/Dana Farber, she worked at Memorial Sloan Kettering Cancer Center in New York City for a decade. Her research has focused on evaluating the quality of cancer care delivery in the United States. She has methodological expertise in analyzing large public health data sets including tumor registry data, Medicare and Medicaid data and has worked to augment these data sets to enhance their value for comparative effectiveness research. Her research is funded by the National Cancer Institute and the Agency for Healthcare Research and Quality. She collaborates with leadership of public health departments at the local and state level to foster equitable high quality cancer care and to minimize disparities in outcomes based on non-medical factors such as socioeconomic status and race. She has focused on measuring the difference between the efficacy of cancer treatments in the clinical trial setting as well as their effectiveness when new treatments are adopted broadly at the population level. She has served as an American Society of Clinical Oncology (ASCO) Board Member, is currently a Director of the American Board of Internal Medicine Oncology Section and is the Chair of Comparative Effectiveness Research for the Alliance for Clinical Trials in Oncology.
Dr. Veena Shankaran is an Assistant Professor of Medical Oncology at the University of Washington School of Medicine and an Assistant Member in the Clinical Research Division of the Fred Hutchinson Cancer Research Center. She recently received her Masters Degree from the Pharmaceutical Outcomes Research and Policy Program at the University of Washington. Her clinical focus is in gastrointestinal cancers. Her research focuses on out-of-pocket cancer treatment costs and patient decision-making about expensive oncology drugs. She recently received the Southwest Oncology Group’s Charles Coltman Jr. Fellowship to support a study entitled: "Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer."
Ya-Chen Tina Shih, PhD
The University of Chicago

Dr. Tina Shih is Associate Professor in the Section of Health Medicine, Department of Medicine, Pritzker School of Medicine, Director of Program in Economics of Cancer, and Affiliated Faculty at the Center for Health and the Social Sciences at The University of Chicago. Dr. Shih received her Ph.D. in Economics from Stanford University, with a concentration on labor/health economics and econometrics. She has served as Principal Investigators on research grants related to various economic aspects of cancer funded by the National Cancer Institute, National Human Genome Research Institute, Agency for Healthcare and Quality, American Cancer Society, and Lance Armstrong Foundation.

Dr. Shih has over 15 years of experience with economic evaluation, health services, and comparative effectiveness research, using both modeling approach and econometric techniques applied to observational as well as trial data. Her research concentrates on the application of quantitative methods to examine the economic aspect of cancer care. Major themes in her work include studying the diffusion of new medical technologies among various patients/provider subgroups and/or geographic areas; examining the impact of new technologies in the outcomes and costs of cancer care; and exploring the effect, especially the unintended consequences, of technology diffusion, health policies and regulations on cancer patients. Other research interests are assessing the cost-effectiveness of medical as well as behavioral interventions. Dr. Shih has over 70 publications, serves a co-editor for *Value in Health*, and is on the editorial board of *PharmacoEconomics*. She is a member of the National Cancer Policy Forum at the Institute of Medicine of the National Academy of Sciences and also serves on the American Cancer Society Guidelines Development Workgroup.
Jennifer Temel, MD  
Massachusetts General Hospital Cancer Center  

Dr. Jennifer Temel is an Associate Professor of medicine at Harvard Medical School and the Clinical Director of Thoracic Oncology at Massachusetts General Hospital Cancer Center. She attended Cornell University for her undergraduate degree and received her MD at Washington University in St. Louis. She completed her medical residency at Brigham and Women’s Hospital and her Oncology Fellowship at the Dana Farber/Massachusetts General Hospital combined training program. She has been an attending physician at MGH for over 10 years and cares for patients with both lung and esophageal cancer. Dr. Temel is also the Deputy Director of the Hematology/Oncology Fellowship Training Program and oversees many of the educational efforts at the Cancer Center. Her research interests include optimizing the delivery of care for both the lung cancer patient and their families. She has received funding from the National Cancer Institute, the American Society of Clinical Oncology and the American Cancer Society to study novel methods of improving the care of lung cancer patients. One of the main focuses of her research involves the integration of palliative and oncology care in patients with lung cancer. Her work in this area has been published in the New England Journal of Medicine and the Journal of Clinical Oncology. She has recently received funding from the National Institute of Nursing Research to further study the role and implications of early palliative care in patients with incurable malignancies.
Dr. Robin Yabroff is an epidemiologist in the Health Services and Economics Branch of the National Cancer Institute (NCI). Before joining the NCI in 2002, she was a Research Assistant Professor in the Lombardi Cancer Center at Georgetown University. Dr. Yabroff’s research uses observational data to estimate different aspects of the burden of cancer and improve understanding of factors associated with the receipt of cancer screening, treatment, survivorship care, and end-of-life care. Dr. Yabroff has received several NIH Merit Awards, including one for Economic Studies Related to Cancer Burden and Control. She has published extensively in peer-reviewed journals in health services research related to cancer. She is an associate editor for the Journal of the National Cancer Institute and a member of the editorial board of the Journal of Cancer Survivorship. She was a guest editor for a recent Medical Care journal supplement, Health Care Costing: Data, Methods, Future Directions. Dr. Yabroff is currently leading a collaborative effort to improve publicly available data for estimating the burden of cancer in the US, the Medical Expenditure Panel Survey (MEPS): Experiences with Cancer Survivorship Supplement. Dr. Yabroff received her doctorate in epidemiology from The Johns Hopkins University School of Hygiene and Public Health and her MBA from the University of Rochester. She received a B.S. in biology and a B.A. in psychology from Indiana University.